Patents Assigned to Agenovir Corporation
  • Compositions and methods to treat herpes simplex virus infections
    Patent number: 10117911
    Abstract: Herpes simplex virus (HSV) including herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are a persistent cause of human disease with no known cure. Guided nuclease systems target specific regions of the HSV-1 and HSV-2 genomes, disrupting the virus' nucleic acid and rendering even latent viruses incapacitated.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 6, 2018
    Assignee: Agenovir Corporation
    Inventors: Stephen R. Quake, Jianbin Wang